Additional Listing

Phytopharm PLC
18 August 2004

                                 August 18 2004



 Phytopharm Announces its Completion of a Level-I ADR Program and its Intention
                               to List on NASDAQ



Phytopharm plc (PYM: London Stock Exchange) ('Phytopharm') announces today the
establishment of a Level-I American Depositary Receipt (ADR) program and its
intention to list on NASDAQ. The Level-I program represents the first step in
listing Phytopharm's securities on NASDAQ. The Bank of New York has been
appointed as the depositary bank for the Level-I ADR program and the New York
based investment bank, Global Markets Capital Group, LLC will manage the listing
process.



The code for Phytopharm's ADR is PHYOY and its CUSIP number is 71942W101. Each
Phytopharm ADR represents two ordinary shares of Phytopharm, as traded on the
London Stock Exchange. Trading activity may be viewed on the Bloomberg website,
www.bloomberg.com.



'Phytopharm sees this as an important first step towards achieving a full US
listing of our shares,' said Dr. Richard Dixey, CEO of Phytopharm.



'An ADR program will allow Phytopharm to penetrate the very important US capital
markets. There is considerable US investor interest in our portfolio,
particularly our products for obesity, Alzheimer's and motor neurone disease
(Lou Gehrig's disease), and it is important that US investors have a convenient
mechanism to buy our securities. This ADR program will facilitate the purchase
of Phytopharm shares by US investors.'



ENQUIRIES:


Phytopharm plc                                                                       Tel: [phone]
Dr. Richard Dixey, Chief Executive Officer                                                [phone]

Financial Dynamics                                                                  Tel: [phone]
David Yates / Ben Atwell

Global Markets Capital Group, LLC                                                    Tel: [phone]
Mark Saunders, President



                               www.phytopharm.com





ABOUT PHYTOPHARM

Phytopharm is a leading company in the development of Botanical pharmaceuticals.
These plant-based medicines, manufactured to pharmaceutical standards, can be
clinically evaluated in chronic and poorly understood diseases. Where novel
modes of action are discovered, such research can form the basis for drug
discovery platforms, which enable the development of new medicines and the
isolation of single chemical entities of clinical importance. Phytopharm has
four drug discovery platforms in full development, for metabolic disease,
neurodegeneration, inflammation and dermatology. For more information, visit the
company's website at www.phytopharm.com.



For the benefit of shareholders the following information is provided:



ABOUT AMERICAN DEPOSITARY RECEIPTS (ADRS)

ADRs are commonly used to facilitate U.S. investors investing in foreign
companies not listed in the USA. An ADR is created when a broker purchases the
company's shares on the home stock market and delivers those to the depositary's
local custodian bank, which then instructs the depositary bank, The Bank of New
York, to issue ADRs. Level-I ADRs may trade freely, just like any other
security, in the U.S. Over-the-Counter (OTC) market.






                      This information is provided by RNS
            The company news service from the London Stock Exchange